Cargando…

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells

Detalles Bibliográficos
Autores principales:	Stefka, A T, Park, J-H, Matsuo, Y, Chung, S, Nakamura, Y, Jakubowiak, A J, Rosebeck, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022182/ https://www.ncbi.nlm.nih.gov/pubmed/27540718 http://dx.doi.org/10.1038/bcj.2016.71

Ejemplares similares

Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
por: Stefka, Andrew T., et al.
Publicado: (2019)

Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1
por: Fujiwara, Shiho, et al.
Publicado: (2015)

Myeloma therapy: pursuing the plasma cell
por: Cavenagh, J
Publicado: (2010)

Enhancement of myeloma development mediated though myeloma cell-Th2 cell interactions after microbial antigen presentation by myeloma cells and DCs
por: Tian, F, et al.
Publicado: (2012)

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
por: Yousef, S, et al.
Publicado: (2015)

Extracellular crystals in plasma cell myeloma
por: Brown, Jacqueline T., et al.
Publicado: (2014)

Plasma Cell Myeloma Masquerading as Scleromyxedema
por: Victor, Varun, et al.
Publicado: (2019)

Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
por: Derman, Benjamin A., et al.
Publicado: (2020)

Towards Stratified Medicine in Plasma Cell Myeloma
por: Egan, Philip, et al.
Publicado: (2016)

In vitro osteolytic activity of human myeloma plasma cells and the clinical evaluation of myeloma osteoclastic bone lesions.
por: Rossi, J. F., et al.
Publicado: (1984)

Giant multinucleated plasma cells in relapsed plasma cell myeloma
por: Ghattas, Sylvia, et al.
Publicado: (2020)

Phenotypic consensus markers for plasma cell myeloma
por: Hur, Mina
Publicado: (2012)

Toothache as the initial symptom of plasma cell myeloma
por: Wehrhahn, Tobias, et al.
Publicado: (2018)

Plasmablastic myeloma progressed to plasma cell leukaemia
por: Xu, Ke, et al.
Publicado: (2021)

Multifocal Extramedullary Plasma Cell Myeloma of the Colon
por: Karime, Christian, et al.
Publicado: (2023)

Artificial Intelligence in Plasma Cell Myeloma: Neural Networks and Support Vector Machines in the Classification of Plasma Cell Myeloma Data at Diagnosis
por: Yenamandra, Ashwini K., et al.
Publicado: (2021)

The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma
por: Giannakoulas, Nikolaos, et al.
Publicado: (2021)

Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2022)

The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Biological Insights into Myeloma and Other B Cell Malignancies
por: Fulciniti, Mariateresa, et al.
Publicado: (2016)

Natural Killer Cells in the Malignant Niche of Multiple Myeloma
por: Venglar, Ondrej, et al.
Publicado: (2022)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Simultaneous presentation of plasma cell myeloma and hairy cell leukemia
por: Carulli, Giovanni, et al.
Publicado: (2019)

Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma
por: Choi, Qute, et al.
Publicado: (2010)

Plasma Cell Myeloma Initially Presenting as Lung Cancer
por: Cho, Sun Young, et al.
Publicado: (2013)

Bone Marrow Gouty Tophi With Plasma Cell Myeloma
por: Bang, Hae In, et al.
Publicado: (2020)

Anaplastic plasma cell myeloma — A morphological dilemma
por: Raman Ramalingam, Thulasi, et al.
Publicado: (2022)

Flower-Like Plasma Cell Nuclei in Multiple Myeloma
por: Sall, Abibatou, et al.
Publicado: (2021)

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma
por: Blatt, Katharina, et al.
Publicado: (2016)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2–myeloma cell interaction
por: Tian, Faqing, et al.
Publicado: (2019)

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells
por: Li, Juan, et al.
Publicado: (2016)

Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study
por: Derman, Benjamin A, et al.
Publicado: (2020)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
por: Caraux, Anouk, et al.
Publicado: (2012)

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
por: Oberle, Anna, et al.
Publicado: (2017)

Renal cell carcinoma and plasma cell myeloma: Coincidence or true association?
por: Mubarak, Muhammed
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_is3ad2j9tr3rj8ihfeo3ph86ef